— Know what they know.
Not Investment Advice
Also trades as: MSB.AX (ASX) · $vol 4M · MEOBF (OTC) · $vol 0M

MESO NASDAQ

Mesoblast Limited
1W: +3.7% 1M: -18.1% 3M: -14.3% YTD: -31.8% 1Y: -27.5% 3Y: +420.6% 5Y: +8.1%
$13.18
+0.79 (+6.38%)
After Hours: $12.92 (-0.26, -1.97%)
Weekly Expected Move ±7.7%
$10 $11 $12 $13 $14
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 34 · $1.6B mcap · 86M float · 0.282% daily turnover · Short 49% of daily vol
Credit Risk of going bust: lower than 58% of companies Debt: 7.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.11 (down 99.1%), Mesoblast Limited would be worth roughly what it owes.
Total debt $127.3M against a stock market value of $1.61B.
Distance to default 6.03 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $64.9M (short-term plus half of long-term), stock volatility 54.3%; Altman Z'' -1.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$121M
Revenue
+602.3% YoY
$-58M
Net Income
+43.7% YoY
$-42M
Free Cash Flow
+13.0% YoY
141.0%
Gross Margin
-58.6%
Op. Margin
-24.8%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-9.9%
ROA-7.4%
ROIC-14.4%

Valuation

P/E-29.4
P/B3.0
EV/EBITDA-42.0

Leverage

Debt/Equity0.22
Current Ratio2.43
Interest Cov.-4.5x

Quality Scores

Piotroski F5/9
Altman Z3.33
Beneish M-0.48

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms